LCM
SNNA

Laurion Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Laurion Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,000
Closed -$556K – 1992
2017
Q3 		$556K Buy
+25,000
New +$549K ﹤0.01% 1137

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurion Capital Management's SNNA Position: Q4 2017 in Review

Laurion Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2017, closing a stake of 25,000 shares — an estimated $556K sold.

Laurion Capital Management first reported a position in SNNA in Q3 2017 and held it in 1 quarter. The position peaked at $556K in Q3 2017. 43 funds tracked by Wall St. Rank hold SNNA as of Q4 2017.

  • Laurion Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Laurion Capital Management sold 25,000 Sienna Biopharmaceuticals, Inc. shares in Q4 2017, an estimated $556K.
  • Laurion Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Laurion Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $556K in Q3 2017.
  • 43 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.